In a report released today, Raju Prasad from William Blair maintained a Buy rating on Crispr Therapeutics AG (CRSP). The companys shares closed last Wednesday at $94.30.

According to TipRanks.com, Prasad is a 5-star analyst with an average return of 13.4% and a 53.9% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Alexion Pharmaceuticals, and Rocket Pharmaceuticals.

Currently, the analyst consensus on Crispr Therapeutics AG is a Strong Buy with an average price target of $95.88, implying a 5.1% upside from current levels. In a report released today, Needham also assigned a Buy rating to the stock with a $105.00 price target.

See todays analyst top recommended stocks >>

The company has a one-year high of $111.90 and a one-year low of $32.30. Currently, Crispr Therapeutics AG has an average volume of 870.1K.

Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.

View post:
William Blair Sticks to Its Buy Rating for Crispr Therapeutics AG (CRSP) - Smarter Analyst

Comments are closed.